Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | NAT1 | P18440 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490744 | 0.86 | TRIM24 (0.52) | CYP2A6TRIM24TRIM33ALDH1A1CA12 | |
| SCHEMBL13638172 | 0.85 | ALDH1A1 (0.53) | TRIM24TRIM33ALDH1A1CA12CA1 | |
| SCHEMBL13250832 | 0.82 | TRIM24 (0.53) | CYP2A6TRIM24TRIM33ALDH1A1CA12 | |
| SCHEMBL23244698 | 0.81 | CYP2A6 (0.52) | CYP2A6ERN1SCN9ATNKS2AOC3 | |
| SCHEMBL12577712 | 0.81 | BRD4 (0.50) | CYP2A6TRIM24TRIM33ALDH1A1CA12 | |
| SCHEMBL2563109 | 0.80 | TRIM24 (0.53) | TRIM24TRIM33ALDH1A1CA12CA1 | |
| SCHEMBL12577714 | 0.80 | ESR1 (0.51) | TRIM24TRIM33ALDH1A1CA12CA1 | |
| SCHEMBL29628996 | 0.80 | CYP2A6 (0.71) | CYP2A6SCN9ATNKS2AOC3KAT6A | |
| SCHEMBL9479255 | 0.80 | CYP2A6 (0.71) | CYP2A6SCN9ATNKS2AOC3KAT6A | |
| SCHEMBL29700474 | 0.79 | TRIM24 (0.46) | CYP2A6TRIM24TRIM33ALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390247-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-07 | — | — | US | disclosed |
| EP-4257583-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Institute of Science and Technology (KR) | 2023-10-11 | — | — | EP | disclosed |
| CN-103923060-B | Oseltamivir derivative and its preparation method and application | SHANDONG UNIVERSITY (CN) | 2016-05-25 | — | — | CN | disclosed |
| US-8883796-B2 | Biphenyl derivatives, pharmaceutical composition comprising the same, and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-11-11 | — | — | US | disclosed |
| US-20140228568-A1 | BIPHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-08-14 | — | — | US | disclosed |
| CN-103923060-A | Oseltamivir derivative as well as preparation method and application thereof | UNIV SHANDONG | 2014-07-16 | — | — | CN | disclosed |
| CN-101413143-B | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST | 2013-09-18 | — | — | CN | disclosed |
| CN-102240278-A | Methods, assays and compositions for treating retinol-related diseases | SYTERA INC | 2011-11-16 | — | — | CN | disclosed |
| CN-101072555-B | Methods, assays and compositions for treating retinol-related diseases | SYTERA INC | 2011-06-29 | — | — | CN | disclosed |
| EP-1501509-A4 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| CN-100448852-C | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2009-01-07 | — | — | CN | disclosed |
| CN-101252924-A | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | SIRION THERAPEUTICS INC (US) | 2008-08-27 | — | — | CN | disclosed |
| CN-101218223-A | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH CORP (US) | 2008-07-09 | — | — | CN | disclosed |
| US-7348348-B2 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK & CO. INC. (US) | 2008-03-25 | — | — | US | disclosed |
| CN-101129344-A | Methods, assays and compositions for treating retinol-related diseases | SYTERA INC (US) | 2008-02-27 | — | — | CN | disclosed |
| CN-101072555-A | Methods, assays and compositions for treating retinol-related diseases | SYTERA INC (US) | 2007-11-14 | — | — | CN | disclosed |
| CN-1747965-A | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2006-03-15 | — | — | CN | disclosed |
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
| EP-1501509-A2 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004024061-A2 | ARYL-LINK-ARYL SUBSTITUTED THIAZOLIDINE-DIONE AND OXAZOLIDINE-DIONE AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | KCNN1, KCNH1, KCNN2 | CYP2A6 2038/4885TRIM24 3004/4885TRIM33 3859/4885 |
| US-20140228568-A1 | BIPHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND PREPARATION METHOD THEREOF | HTR7, HTR6, HTR3B | CYP2A6 59/4885TRIM24 4797/4885TRIM33 3683/4885 |
| US-20230390247-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | HTR7, TPH1, HTR2C | CYP2A6 717/4885TRIM24 3909/4885TRIM33 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.